MGMT and glioblastoma: When discussing the differences in the response of the tested glioblastoma cell lines to mephedrone, it is necessary to take into account changes in the methylation level of the MGMT promoter, which is a useful tool for predicting the treatment outcome for patients with glioblastoma undergoing chemotherapy with alkylating drugs, including temozolomide [38].